Tharimmune Inc (THAR)

06:08 AM

Tharimmune Abandons Acquisition of Intract Pharma - MarketWatch

06:08 AM

Nov 19, 2024

Valsoft Corporation Enters the Book Industry Software Space with the Acquisition of Edelweiss - Corsicana Daily Sun

Nov 19, 2024

Nov 18, 2024

What's Going On With Tharimmune Shares Monday? - Benzinga

Nov 18, 2024

Nov 18, 2024

Tharimmune Presents Positive Clinical Data at AASLD the Liver Meeting(R) to Support TH104 for Chronic Pruritus in Chronic Liver Disease - Brazosport Facts

Nov 18, 2024

Nov 14, 2024

Pre-market Movers: ELAB, PHGE, CLDI, BJDX... - RTTNews

Nov 14, 2024

Nov 14, 2024

Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock - Investing.com India

Nov 14, 2024

Nov 13, 2024

Tharimmune COO Appajosyula Sireesh acquires $10,096 in stock By Investing.com - Investing.com Canada

Nov 13, 2024

Nov 13, 2024

Tharimmune set to receive European patent for cancer therapy tech By Investing.com - Investing.com Canada

Nov 13, 2024

Nov 13, 2024

What's Going On With Tharimmune Shares Wednesday? - MSN

Nov 13, 2024

Nov 13, 2024

Tharimmune set to receive European patent for cancer therapy tech - Investing.com

Nov 13, 2024

Nov 13, 2024

Tharimmune Secures Key European Patent for Revolutionary Nanoparticle Drug Delivery System | THAR Stock News - StockTitan

Nov 13, 2024

Nov 04, 2024

Tharimmune Announces Upcoming Conference Presentations - StockTitan

Nov 04, 2024

Nov 01, 2024

U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN

Nov 01, 2024

Oct 31, 2024

Dow Surges Over 150 Points; Alphabet Posts Upbeat Results - MSN

Oct 31, 2024

Oct 31, 2024

United States shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN

Oct 31, 2024

Oct 31, 2024

U.S. shares lower at close of trade; Dow Jones Industrial Average down 0.22% - MSN

Oct 31, 2024

Oct 30, 2024

S&P 500 Edges Lower; US Crude Oil Inventories Fall - MSN

Oct 30, 2024

Oct 30, 2024

New Jersey-Based Biotech Company Finds Massive Mid-Week Success Following "Positive Feedback" - MSN

Oct 30, 2024

Oct 30, 2024

Crude Oil Gains Over 2%; Eli Lilly Cuts 2024 Forecast - Benzinga

Oct 30, 2024

Oct 30, 2024

S&P 500 Total Return (TCU24) Quote - The Globe and Mail

Oct 30, 2024

Oct 30, 2024

Triller Group Inc. (NASDAQ: ILLR) Reversing as Shorts Run for Coversee more stocks inside... - openPR

Oct 30, 2024

Oct 30, 2024

Tharimmune (THAR) Stock Rallies After Positive EMA Feedback Boosts Confidence - Stocks Telegraph

Oct 30, 2024

Oct 30, 2024

Tharimmune receives regulatory feedback from EMA for TH104 program - TipRanks

Oct 30, 2024

Oct 30, 2024

Tharimmune secures EMA feedback on pruritus drug trial - Investing.com

Oct 30, 2024

Oct 30, 2024

Tharimmune Receives Positive Regulatory Feedback From EMA for TH104 Clinical Program for Chronic Pruritus in Primary Biliary Cholangitis - StockTitan

Oct 30, 2024

Oct 28, 2024

TH104 trial shows promise for liver disease-related itch relief By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 28, 2024

TH104 trial shows promise for liver disease-related itch relief - Investing.com

Oct 28, 2024

Oct 28, 2024

Tharimmune presents TH104 Phase 1 data at ACG Annual Meeting - TipRanks

Oct 28, 2024

Oct 28, 2024

Tharimmune Presents Favorable TH104 Phase 1 Clinical Data at the American College of Gastroenterology 2024 Annual Scientific Meeting - Milton Daily Standard

Oct 28, 2024

Oct 11, 2024

Tharimmune CEO Randy Milby buys $5.2k in company stock - Investing.com India

Oct 11, 2024

Oct 11, 2024

Tharimmune CEO Randy Milby buys $5.2k in company stock By Investing.com - Investing.com Australia

Oct 11, 2024

Oct 08, 2024

Tharimmune COO acquires $9,650 in company stock - Investing.com

Oct 08, 2024

Oct 08, 2024

Tharimmune COO acquires $9,650 in company stock By Investing.com - Investing.com UK

Oct 08, 2024

Oct 01, 2024

Biohaven aims to raise $250M; Activist investor’s stake in Galapagos exceeds 10% - Endpoints News

Oct 01, 2024

Sep 30, 2024

Tharimmune Announces Intent to Acquire Intract Pharma - TipRanks

Sep 30, 2024

Sep 30, 2024

Tharimmune signs nonbinding LOI to merge with Intract Pharma - TipRanks

Sep 30, 2024

Sep 30, 2024

Tharimmune Signs Nonbinding Letter of Intent to Merge With Intract Pharma to Create Transformative Oral Biologic Therapeutics Company - StockTitan

Sep 30, 2024

Sep 25, 2024

Hillstream Biopharma stock plunges to 52-week low of $2.52 - Investing.com India

Sep 25, 2024

Sep 16, 2024

Tharimmune Expands Immunology Pipeline with Intract License - TipRanks

Sep 16, 2024

Sep 16, 2024

Tharimmune Acquires Global License and Partners With Intract Pharma to Develop an Oral Formulation of Infliximab - StockTitan

Sep 16, 2024

Aug 13, 2024

Tharimmune, Inc. (NASDAQ:THAR) Short Interest Down 35.7% in July - Defense World

Aug 13, 2024

Jul 22, 2024

Tharimmune Appoints Prof. David Jones of Newcastle University to its Scientific Advisory BoardChannel3000.com - Channel3000.com - WISC-TV3

Jul 22, 2024

Jul 17, 2024

Tharimmune adds David Clarke as Strategic Advisor - Investing.com

Jul 17, 2024